- 92 Mansour D. Qlaira[®]: a 'natural' change of direction. *J Fam Plann Reprod Health Care* 2009; **35**: 139–142.
- 93 Koetsawang S, Mandlekar AV, Krishna UR, Uurandare VN, Deshpande CK, et al.; for the Task Force on Oral Contraceptives. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. Contraception 1980; 21: 445–459.
- 94 Wenzl R, Bennink HC, van Beek A, Spona J, Huber J. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol. *Fertil Steril* 1993; 60: 616–619.
- 95 Hirvonen E, Allonen H, Anttila M, Kulmala Y, Ranta T, Rautiainen H, *et al.* Oral contraceptive containing natural estradiol for premenopausal women. *Maturitas* 1995; **21**: 27–32.
- Mueck AO, Seeger H, Buhling KJ. Why use of dienogest for the first contraceptive pill with estradiol? *Gynecol Endocrinol* 2009; **August 11**, 1–5 [Epub ahead of print] DOI: 10.3109/ 09513590903184167.
- 97 Sasagawa S, Shimizu Y, Kami H, Takeuchi T, Mita S, Imada K, *et al.* Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. *Steroids* 2008; **73**: 222–231.
- 98 Dusterberg B, Nishino Y. Pharmacokinetic and

- pharmacological features of oestradiol valerate. *Maturitas* 1982; 4: 315–324.
- 99 Ahrendt HJ, Makalova D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. *Contraception* 2009; **80**: 436–444.
- 100 Chabbert-Buffet N. Synergistic effect of 17β-estradiol and nomegestrol acetate used in a new monophasic oral contraceptive. Paper presented at the 8th Congress of the European Society of Gynecology, Rome, Italy, 10–13 September 2009.
- 101 Serfaty D, Christin Maitre S, Ochsenbein E, Thomas J-L. Comparison of two regimens of new monophasic oral contraceptive combining 17 beta-estradiol and nomegestrol acetate. Paper presented at the XIX FIGO World Congress of Gynecology and Obstetrics, Cape Town, South Africa, 4–9 October 2009.
- 102 Catherino WH, Jordan VC. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995; 55: 239–246.
- 103 Ezan E, Benech H, Bucourt R, Ardouin T, Tchernatinsky C, Thomas JL, et al. Enzyme immunoassay for nomegestrol acetate in human plasma. J Steroid Biochem Mol Biol 1993; 46: 507–514.

FACULTY OF SEXUAL & REPRODUCTIVE HEALTHCARE MEMBERSHIP EXAMINATION

The Membership Examination (MFSRH) consists of:

□ Part 1 Multiple Choice Question paper (MCQ)

The London-based examination is held annually in April and October. Applications for the 14 April 2011 examination must be received by 4 January 2011. Applications for the 19 October 2011 examination must be received by 1 July 2011. The new syllabus for the Part 1 is on the Faculty website.

□ Evidence Based Commentary (EBC)

Candidates can view the released topic and candidate guidance notes for EBC on the Faculty website. There is an **absolute deadline** of **31 August 2011** to submit the EBC on this topic.

□ Part 2 Examination (CRQ, SAQ, OSCE)

This all-day examination will consist of:

- Critical Reading Question examination paper (CRQ)
- Extended Matching Question examination paper (EMQ)
- Objective Structured Clinical Examination (OSCE)

Applications for the MFSRH Part 2 held on 15 June 2011 must be received by **4 January 2011**. The new Part 2 Syllabus is on the Faculty website.

The qualification is subject to re-certification every 5 years.

For the current MFSRH Examination Regulations, information on all components of the MFSRH examination and application forms, please visit the Faculty of Sexual and Reproductive Healthcare website: www.fsrh.org (Training & Exams and Membership Exam) or e-mail Denise Pickford: denise@fsrh.org.

JOIN THE PANEL OF MFSRH EXAMINERS

The Faculty Examination Committee invites applications to join the panel of MFSRH Examiners for the Membership Examination. Applications are sought only from those able to **fully commit to all examiner duties** and who meet the following criteria:

- To be accredited Members of the Faculty and active clinically in the sphere of the Faculty or to be Clinicians, of equivalent status, with an interest in Sexual and Reproductive Healthcare but whose speciality is Genitourinary Medicine (GUM), Public Health Medicine, Gynaecology or Primary Care.
- To be able to show excellence in the quality of patient care, research skills or teaching skills relevant to the sphere of the Faculty.
- To hold or have held the Faculty Letter of Competence in Medical Education or equivalent. Further information and the examiner CV application form are available on the Faculty website: www.fsrh.org (Training & Exams, Membership Exam, MFSRH Examiners). The closing date for applications is 6 January 2011 and the form should be sent to the Examination Secretary, Examinations, FSRH, 27 Sussex Place, Regent's Park, London NW1 4RG, UK. Tel: +44 (0) 20 7724 5629. Fax: +44 (0) 20 7723 5333.